BLACKROCK INCOME AND GROWTH INVESTMENT TRUST PLC
All information is at 28 June 2013 and unaudited.
Performance at month end with net income reinvested
One Three One Since Three Five
month months year 1 April years years
2012
Sterling:
Share price -5.2% -1.0% 23.3% 21.4% 38.6% 17.2%
Net asset value -4.8% -2.1% 13.5% 11.8% 37.2% 13.2%
FSTE All-Share Total Return -5.0% -1.7% 17.9% 14.8% 43.5% 38.2%
Sources: BlackRock and Datastream
BlackRock took over the investment management of the Company with effect from
1 April 2012.
At month end
Sterling:
Net asset value - capital only: 150.25p
Net asset value - cum income*: 154.49p
Share price: 153.50p
Total assets (including income): £42.8m
Discount to cum-income NAV: 0.6%
Gearing: 4.0%
Net yield**: 3.4%
Ordinary shares in issue***: 27,729,268
Gearing range (as a % of net assets) 0-20%
* includes net revenue of 4.24 pence per share
** based on final dividend of 3.45p per share in respect of the year ended 31
October 2012 and an interim dividend of 1.80p per share in respect of the year
ended 31 October 2012.
*** excludes 5,204,664 shares held in treasury
Benchmark
Sector Analysis Total assets( %)
Oil & Gas Producers 12.7
Banks 12.3
Pharmaceuticals & Biotechnology 10.0
Tobacco 9.7
Food Producers 5.7
Mobile Telecommunications 5.3
Travel & Leisure 4.9
Mining 4.9
Non- Life Insurance 4.7
Life Insurance 4.0
Financial Services 3.8
Support Services 3.4
Media 2.8
Gas, Water & Multiutilities 2.3
General Retailers 2.3
Real Estate Investment & services 2.1
Electronic & Electrical Equipment 2.1
Industrial Engineering 1.5
Oil Equipment, Services & Distribution 1.4
Fixed Line Telecommunications 1.4
Household Goods & Home Construction 1.1
General Industrials 1.0
Non-Equity Investment Instruments 0.7
Net Current Liabilities (0.1)
-------
Total 100.00
-------
Ten Largest Equity Investments
Company % of Total assets
HSBC 7.1
Royal Dutch Shell B 7.0
British American Tobacco 6.2
GlaxoSmithKline 5.9
Vodafone 5.5
Imperial Tobacco 4.0
Barclays 3.6
Shire 3.4
Unilever 3.1
Admiral 3.0
Commenting on the markets, Adam Avigdori, representing the Investment Manager
noted:
Markets
With economic news improving in most of the developed world, many of the major
equity markets have marched steadily upwards over the past year, helped by the
actions taken by central banks around the world to boost the global economy. At
the end of May, however, most global markets were impacted by a statement from
the US Federal Reserve that laid out a timetable for withdrawing its
quantitative easing programme earlier than had been anticipated which sent
equity, bond and commodity markets lower worldwide. The FTSE All-Share Index
saw its first monthly fall in a year in June, down by 5.0% for the month and
down by almost 2.0% during the second quarter. Miners were the most negative
contributors to overall index performance in the second quarter, after an
equally poor contribution during the first quarter. Companies with more
defensive earnings, such as pharmaceuticals and telecoms, were positive
contributors to market returns in the second quarter.
Portfolio Performance
The portfolio returned -4.8% in June, slightly ahead of the FTSE All-Share
Index return of -5.0%.
The positive contributors included Tate & Lyle, the supplier of speciality
ingredients to the food and beverages industries, which has benefited from the
market's re-appraisal of its new management team and strategy, reporting good
results and profit growth.
Carphone Warehouse was a positive contributor to relative returns after
announcing the buyout of its joint venture partner Best Buy and stronger than
expected revenues from its UK operations. Best Buy originally purchased 50% of
Carphone Warehouse Europe in a joint venture for $2.1bn in 2008, and at the end
of June Carphone Warehouse Group bought out its JV partner for $775 million as
Best Buy refocuses on its US business.
We purchased a new holding in Partnership Assurance in the IPO as we believe
the company will demonstrate above market earnings growth and the shares
outperformed following the IPO, which was priced on a market rating. This
company is a specialist insurer that provides financial products to people with
a wide variety of health conditions that are likely to reduce their life
expectancy.
The largest detractor from performance was the holding in Oxford Instruments,
the provider of high technology tools and systems for research and industry.
The shares were down in June after the company highlighted some weakness in end
markets when announcing its full year results. We took the opportunity of the
share price weakness to add to the position.
Copper miner Antofagasta detracted from returns, but having an underweight
position in BHP Billiton and not owning Anglo American, Rio Tinto and Glencore
Xstrata were all positive for relative returns. Overall, the portfolio's
underweight exposure to mining was positive for relative performance as the
sector continued to suffer from demand concerns and commodity price weakness.
We sold the portfolio's holdings of Diageo and Prudential and initiated new
positions in Unilever and Partnership Assurance Group. We reduced the holdings
of HSBC and UBM and added to the Reed Elsevier position.
Outlook
Global GDP growth forecasts remain positive but are still being revised
downwards, in part due to the slowing growth of the emerging economies and
China in particular. UK equity valuations still look attractive compared to
those of most other asset classes, with the prospect of high quality earnings
and dividend growth. We continue to focus on income, stock selection and
building a high conviction portfolio to deliver both income and capital growth.
16 July 2013
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.